sur BioVersys AG
BioVersys Schedules Release of Half-Year 2025 Financial Results
BioVersys AG, a clinical stage biopharmaceutical company listed on SIX (BIOV), announced its plan to release the financial results for the first half of 2025. The company, based in Basel, Switzerland, specializes in developing novel antibacterial treatments targeting multidrug-resistant bacteria.
The financial results will be published on September 10, 2025, at 7:00 AM CET. A conference call and webcast are scheduled for the same day at 2:00 PM CET, where the management will discuss the results and provide a business update. Investors, analysts, and journalists will have the opportunity to engage directly by asking questions.
Participants interested in joining the call need to register to receive dial-in details. BioVersys emphasizes muting browser audio during the session to ensure clarity of communication during the conference.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioVersys AG